Related Experiment Videos
Soluble CD16 in the treatment of murine lupus nephritis
H Watanabe1, D Sherris, G S Gilkeson
1Ralph H. Johnson VA Medical Center and the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, 29425, USA.
Abstract:
To determine if soluble CD16 (sCD16) could alter the expression of lupus-like disease, groups of 10 female NZB/NZW mice (age 16-20 weeks) were given sCD16 three times a week for 5 weeks (control; 100 microg; 200 microg/dose) after onset of proteinuria. Results of this study indicate that the administration of sCD16 after onset of disease lowered anti-DNA levels, delayed the development of proteinuria, and significantly prolonged survival while the mice were on treatment. These results indicate that sCD16 alters the expression of autoantibodies and the progression of renal disease in NZB/NZW mice, suggesting that therapies directed at Fc receptors may be useful in the treatment of SLE.
Insights
Soluble CD16 (sCD16) treatment in mice with lupus-like disease reduced autoantibodies and slowed kidney disease progression. This suggests Fc receptor-targeted therapies may benefit Systemic Lupus Erythematosus (SLE) patients.
Area of Science:
- Immunology
- Rheumatology
- Autoimmune Diseases
Background:
- Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by autoantibody production and organ damage.
- NZB/NZW mice serve as a model for studying lupus-like disease, exhibiting autoantibodies and renal pathology.
- The role of Fc receptors in SLE pathogenesis is an area of active research.
Purpose of the Study:
- To investigate the therapeutic potential of soluble CD16 (sCD16) in a murine model of lupus-like disease.
- To determine if sCD16 administration can modulate autoantibody levels and renal disease progression.
- To assess the impact of sCD16 on survival in NZB/NZW mice with established proteinuria.
Main Methods:
- Female NZB/NZW mice (16-20 weeks old) with proteinuria were treated with sCD16 (100 or 200 microg/dose) thrice weekly for 5 weeks.
- Control groups received no sCD16 treatment.
- Key parameters monitored included anti-DNA antibody levels, proteinuria development, and overall survival.
Main Results:
- sCD16 administration significantly lowered anti-DNA antibody levels.
- Treatment with sCD16 delayed the onset and progression of proteinuria.
- Mice treated with sCD16 exhibited significantly prolonged survival during the treatment period.
Conclusions:
- Soluble CD16 (sCD16) alters the expression of autoantibodies and ameliorates renal disease progression in NZB/NZW mice.
- These findings suggest that therapies targeting Fc receptors, such as sCD16, may hold promise for treating Systemic Lupus Erythematosus (SLE).
- Further research into Fc receptor-modulating agents could lead to novel therapeutic strategies for SLE.